19-334 - Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After SurgeryStatus: open
A PHASE II RANDOMIZED STUDY OF ADJUVANT VERSUS NEOADJUVANT MK-3475 (PEMBROLIZUMAB) FOR CLINICALLY DETECTABLE STAGE III-IV HIGH RISK MELANOMA
Treatment for Melanoma
This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery may work better in treating melanoma.
SponsorsThis trial is sponsored by SWOG.
Interested in Clinical Trial?
- J. Harrison Howard, M.D., F.A.C.S.Surgical OncologistAssociate Professor of Surgery
Providers Associated With This Trial
- Spencer Liles, M.D., F.A.C.S.Surgical OncologistAssistant Professor of Surgery
- Sachin Pai, M.D., M.S.C.I.Medical OncologistProgram Leader of Developmental Therapeutics; Assistant Professor of Interdisciplinary Clinical Oncology
- Moh'd Khushman, M.D.Medical Oncologist and HematologistAssistant Professor of Interdisciplinary Clinical Oncology
- Teja Poosarla, M.D.Medical Oncologist and HematologistAssistant Professor of Interdisciplinary Clinical Oncology